Indeed, bioinformatic analysis of cancer patients treated with genotoxic therapies demonstrates that low expression of ZNF281 is associated with better prognosis, while patients with elevated levels of ZNF281 have a decreased survival probability (Fig. 5). This evidence concerns the gene ZNF281 and cancer.